Evidence map›Paper›PMID 32290110›Full record

ReviewBrain sciences2020

Targeting the Orexin System for Prescription Opioid Use Disorder.

Alessandra Matzeu, Rémi Martin-Fardon

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities.Translational research : the journal of laboratory and clinical medicine · 2021
    Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alessandra MatzeuDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-7654-4149
Rémi Martin-FardonDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
Scripps Research Institute · US

Funding

Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2003 to 2026
$46.3M
Pivotal role of thalamic hypocretin transmission during EtOH seeking and relapseR01AA026999 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARTIN-FARDON, REMI · 2018 to 2022
$2.2M
Merck Investigator Studies Program MISP59371National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism AA006420 and AA026999NIAAA NIH HHS P60 AA006420NIAAA NIH HHS R01 AA026999
6 · The paper itself

Abstract

Prescription opioids are potent analgesics that are used for clinical pain management. However, the nonmedical use of these medications has emerged as a major concern because of dramatic increases in abuse and overdose. Therefore, effective strategies to prevent prescription opioid use disorder are urgently needed. The orexin system has been implicated in the regulation of motivation, arousal, and stress, making this system a promising target for the treatment of substance use disorder. This review discusses recent preclinical studies that suggest that orexin receptor blockade could be beneficial for the treatment of prescription opioid use disorder.

Indexed as

fentanylKeywords: orexinoxycodoneprescription opioid use disorderremifentanil

Identifiers

PMID32290110
PMCPMC7225970
OpenAlexW3015785747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.